Get the latest news, insights, and market updates on BLCO (Bausch + Lomb Corporation). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Bausch Health Cos Q4 Earnings Call Highlights
Bausch Health Cos (NYSE:BHC) executives said the company finished 2025 with its “eleventh consecutive quarter of growth” in revenue and adjusted EBITDA, as management highlighted broad-based commercial execution, improved balance sheet flexibility and a steady pipeline of business development activi Feb 19, 2026 - $BLCO
BLCO Q4 2025 Deep Dive: Dry Eye and Product Innovation Propel Growth, Margin Expansion in Focus
Eyecare company Bausch + Lomb (NYSE:BLCO) announced better-than-expected revenue in Q4 CY2025, with sales up 9.8% year on year to $1.41 billion. The company’s full-year revenue guidance of $5.43 billion at the midpoint came in 0.7% above analysts’ estimates. Its non-GAAP profit of $0.32 per share was 10.3% below analysts’ consensus estimates. Feb 19, 2026 - $BLCO
Bausch + Lomb Q4 Earnings Call Highlights
Bausch + Lomb (NYSE:BLCO) executives highlighted what they described as a record fourth quarter and full-year 2025 performance, driven by broad-based revenue growth, accelerating profitability, and continued momentum in dry eye during the company’s fourth-quarter 2025 earnings call. Record Q4 and f Feb 18, 2026 - $BLCO
1st contact lens innovation since 1999 is coming: Bausch + Lomb CEO
Bausch + Lomb (BLCO) posted mixed fourth quarter results. Although adjusted earnings per share (EPS) came in shy of analyst consensus, the company also posted its highest-ever revenue and EBITDA numbers. Bausch + Lomb CEO Brent Saunders sits down with Opening Bid host Brian Sozzi to break down the three main drivers behind the company's growth. To watch more expert insights and analysis on the latest market action, check out more Opening Bid. Feb 18, 2026 - $BLCO
Bausch + Lomb: Q4 Earnings Snapshot
The average estimate of six analysts surveyed by Zacks Investment Research was for earnings of 35 cents per share. The company posted revenue of $1.41 billion in the period, which beat Street forecasts. Five analysts surveyed by Zacks expected $1.38 billion. Feb 18, 2026 - $BLCO
Bausch + Lomb’s (NYSE:BLCO) Q4 CY2025: Beats On Revenue
Eyecare company Bausch + Lomb (NYSE:BLCO) announced better-than-expected revenue in Q4 CY2025, with sales up 9.8% year on year to $1.41 billion. The company’s full-year revenue guidance of $5.43 billion at the midpoint came in 0.8% above analysts’ estimates. Its non-GAAP profit of $0.32 per share was 10.3% below analysts’ consensus estimates. Feb 18, 2026 - $BLCO
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple